CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: August-12-14
Credit Expiration Date: August-12-15


Patricia K. Coyle, MD
Professor and Vice Chair
Clinical Affairs Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University SUNY
Stony Brook, NY

Stephen Krieger, MD
Assistant Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Director, Neurology Residency Program
Mount Sinai Medical Center
New York, NY

Credit Hours

1.0 AMA PRA Category 1 Credit


Online Presentation

Program Description


An estimated 350,000 to 500,000 people in the United States are currently diagnosed with multiple sclerosis (MS), a chronic neurologic disorder with potential for substantial negative impact on quality of life. A wide variety of neurological symptoms can occur with MS, including tingling and numbness, loss of balance, weakness in one or more limbs, and vision problems. Treatment is focused on returning function after an attack, preventing new attacks, and preventing disability.

The heterogeneity of the pathogenesis of MS and wide variation in the clinical course for each patient make management of MS challenging for clinicians. Neurologists have an opportunity to improve the treatment of MS by expanding their ability to individualize treatment decisions for each patient at each stage of MS. This activity offered participants the opportunity to ask questions of two leading MS experts.

Program Developer/Facilitator


Target Audience

The educational design of this activity addresses the needs of neurologists, neurological nurses, and other health care clinicians involved or interested in the treatment of patients with multiple sclerosis.

In order to obtain credit, participants must complete the activity in full as well as the Post-Test and Evaluation.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss effective and appropriate management strategies for various stages of MS disease course.
  2. Summarize available and novel treatment options to improve patient outcomes in MS.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Patricia K. Coyle, MD, discloses that she is a consultant to Genzyme/Sanofi and Novartis; and has received honoraria from Accordant, Acorda, Bayer, Biogen, EMD Serono, Roche, and Teva.

Stephen Krieger, MD, discloses that he is a consultant to Acorda Therapeutics, Bayer HealthCare, Biogen Idec, Genzyme, Questcor, and Teva Neuroscience; and has received honoraria from Teva Canada.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN: Nothing to disclose
Amanda Glazar, PhD: Nothing to disclose
Gena Dolson: Nothing to disclose

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and MCM Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and MCM Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please contact Global at 303-395-1782 or

This activity is jointly sponsored by Global Education Group and MCM Education.

Commercial Support Statements

This activity is supported by an independent educational grant from Novartis Corporation.

Certificate Fee



©2014, MCM Education. All rights reserved. This activity is designed to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the content may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this webconference are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Global Education Group, or Novartis. Any medications or other diagnostic or treatment procedures presented by the program faculty should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu